Trial Profile

A Phase 1/2 Study of Darolutamide and Abemaciclib in High-Risk Prostate Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 06 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abemaciclib (Primary) ; Darolutamide (Primary) ; Degarelix; Goserelin; Leuprorelin
Indications Adenocarcinoma; Prostate cancer; Transitional cell carcinoma
Focus Adverse reactions; Therapeutic Use
Acronyms Neo-DAB

Most Recent Events

06 Mar 2026 Protocol has been amended(Phase of the trial has been changed from 1/2 to 1).
30 Jul 2024 Planned primary completion date changed from 15 Jul 2024 to 15 Jul 2025.
14 Jun 2024 Planned primary completion date changed from 1 Jun 2024 to 15 Jul 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com